Skip to content

Study · Not a test of the peptide alone · 2023

2 results

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.

Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA14 Oct 2022Cited by 17 (Europe PMC)

PMID36239756 (opens in a new tab)PMCIDPMC9813198 (opens in a new tab)DOI10.1007/s00198-022-06570-0 (opens in a new tab)PepBankPUB-36239756
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In older women with osteoporosis, sequential teriparatide then alendronate reduced vertebral fracture incidence versus alendronate alone.

    In plain wordsIn older women with osteoporosis, sequential teriparatide then alendronate reduced vertebral fractures versus alendronate alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMorphometric vertebral fracture incidence
    Study

    n = 985

    Comparator
    Alendronate monotherapy
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Morphometric vertebral fracture events
    64 per 627.5 person-years
    Sequential therapy group
    Annual incidence rate
    0.102 per person-year
    Sequential therapy group
    Morphometric vertebral fracture events
    126 per 844.2 person-years
    Alendronate monotherapy group
    Annual incidence rate
    0.1492 per person-year
    Alendronate monotherapy group
    Rate ratio
    0.69 ratio
    Sequential therapy versus alendronate
    Rate ratio 95% CI
    0.54 to 0.88 ratio
    Sequential therapy versus alendronate

    Source sentences

    Summary
    The incidence of morphometric vertebral fracture during the 120-week follow-up period in the sequential therapy group (64 per 627.5 person-years, annual incidence rate 0.1020) was significantly lower than that in the monotherapy group (126 per 844.2 person-years, annual incidence rate 0.1492),
    3 context sentences
    Summary · context
    with a rate ratio of 0.69 (95% confidence interval 0.54 to 0.88, P < 0.01).
    Summary · context
    Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture.
    Summary · context
    Of these, 489 and 496, respectively, were included in the main analysis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome

    In this trial of sequential teriparatide then alendronate versus alendronate alone, no patient had a drug-related severe adverse event after 72 weeks.

    In plain wordsIn this trial, no patient had a severe adverse event considered related to study drug after 72 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableStudy-drug-related severe adverse events after 72 weeks
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    After 72 weeks, no patient had a severe adverse event that was considered related to the study drug.
    2 context sentences
    Summary · context
    Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture.
    Summary · context
    Of these, 489 and 496, respectively, were included in the main analysis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.